Profile of the Alere i Influenza A & B assay: A pioneering molecular point-of-care test Journal Article


Authors: Wang, H.; Deng, J.; Tang, Y. W.
Article Title: Profile of the Alere i Influenza A & B assay: A pioneering molecular point-of-care test
Abstract: Introduction: The Alere i Influenza A & B assay incorporates the Nicking Enzyme Amplification Reaction technique on the Alere i instrument to detect and differentiate influenza virus (Flu) A and B nucleic acids in specific specimens. Areas covered: The Alere i Influenza A & B assay was cleared by the US Food and Drug Administration for use with nasal swabs (NS) and nasopharyngeal swabs, either directly or in viral transport medium. Notably, direct use on NS was the first ever CLIA-waived nucleic acid-based test. Previously published evaluations have reported sensitivities and specificities of 55.2–100% and 62.5–100% for Flu A and 45.2–100% and 53.6–100% for Flu B, respectively. Expert commentary: The Alere i Influenza A & B assay provides a rapid and simple platform for detection and differentiation of Flu A and B. Efforts are expected to further improve sensitivity and user-friendliness for effective and widespread use in the true point-of-care setting. © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: influenza viruses a and b; isothermal nucleic acid amplification technology; nasal swabs; nasopharyngeal swabs; nicking enzyme amplification reaction; rapid molecular diagnosis
Journal Title: Expert Review of Molecular Diagnostics
Volume: 18
Issue: 5
ISSN: 1473-7159
Publisher: Informa Healthcare  
Date Published: 2018-01-01
Start Page: 403
End Page: 409
Language: English
DOI: 10.1080/14737159.2018.1466703
PROVIDER: scopus
PUBMED: 29688086
PMCID: PMC6153442
DOI/URL:
Notes: Article -- Export Date: 1 June 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yi-Wei Tang
    188 Tang
  2. Hongmei Wang
    4 Wang